NASDAQ:TRDA
Entrada Therapeutics, Inc.
- Stock
Last Close
17.10
26/07 20:00
Market Cap
584.36M
Beta: -
Volume Today
78.61K
Avg: 47.59K
PE Ratio
−24.93
PFCF: 4.35
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 1.16M - | 1.15M 0.17% | 3.35M 190.12% | 4.63M 38.40% | ||
average receivables | 3.79M - | |||||
book value per share | -1.20 - | -2.03 68.36% | 47.66 2,452.05% | 6.79 85.75% | 7.33 7.96% | |
capex per share | -0.05 - | -0.11 132.39% | -0.73 543.53% | -0.09 87.37% | -0.17 84.12% | |
capex to depreciation | -6.06 - | -7.13 17.73% | -4.10 42.51% | -1.52 62.84% | -1.98 29.71% | |
capex to operating cash flow | 0.06 - | 0.09 55.89% | 0.09 0.97% | 0.03 65.81% | -0.04 230.45% | |
capex to revenue | -0.04 - | |||||
cash per share | 1.31 - | 1.91 45.97% | 46.44 2,335.30% | 6.03 87.01% | 10.65 76.60% | |
days of inventory on hand | ||||||
days payables outstanding | 421.02 - | |||||
days sales outstanding | 21.44 - | |||||
debt to assets | 0.10 - | 0.15 41.32% | ||||
debt to equity | 0.12 - | 0.28 130.72% | ||||
dividend yield | ||||||
earnings yield | -0.02 - | -0.05 257.30% | -0.47 767.50% | -0.21 55.70% | -0.01 93.52% | |
enterprise value | 291.96M - | 451.35M 54.59% | -183.76M 140.71% | 403.86M 319.78% | 499.36M 23.64% | |
enterprise value over ebitda | -24.91 - | -17.13 31.22% | 3.59 120.98% | -4.15 215.55% | -1.56K 37,358.58% | |
ev to operating cash flow | -27.03 - | -17.65 34.70% | 3.61 120.47% | -4.31 219.19% | 3.57 182.95% | |
ev to sales | 3.87 - | |||||
free cash flow per share | -0.89 - | -1.36 53.67% | -8.85 549.29% | -3.09 65.08% | 4.06 231.43% | |
free cash flow yield | -0.04 - | -0.06 53.67% | -0.52 808.33% | -0.23 55.78% | 0.27 217.75% | |
graham net net | -1.31 - | -2.25 71.17% | 45.30 2,117.79% | 4.77 89.48% | 3.96 16.99% | |
graham number | 3.12 - | 7.66 145.27% | 92.56 1,107.69% | 20.67 77.67% | 5.78 72.05% | |
income quality | 2.12 - | 0.96 54.48% | 0.99 3.13% | 0.99 0.30% | -20.91 2,209.80% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | 1.65K - | -36.95 102.24% | ||||
interest debt per share | -0.00 - | 0.91 18,557.81% | 2.06 126.14% | |||
inventory turnover | ||||||
invested capital | 0.12 - | 0.28 130.72% | ||||
market cap | 308.80M - | 490.40M 58.81% | 107.30M 78.12% | 423.09M 294.29% | 498.73M 17.88% | |
net current asset value | -16.32M - | -45.07M 176.17% | 291.58M 746.99% | 170.37M 41.57% | 142.94M 16.10% | |
net debt to ebitda | 1.44 - | 1.48 3.14% | 5.69 284.07% | 0.20 96.53% | -1.96 1,089.83% | |
net income per share | -0.36 - | -1.29 257.30% | -7.99 520.11% | -2.79 65.02% | -0.20 92.76% | |
operating cash flow per share | -0.84 - | -1.25 49.07% | -8.11 549.82% | -3.00 63.07% | 4.23 241.14% | |
payables turnover | 0.87 - | |||||
receivables turnover | 17.02 - | |||||
research and ddevelopement to revenue | 0.75 - | |||||
return on tangible assets | -0.25 - | -0.61 137.75% | -0.16 72.98% | -0.35 111.93% | -0.01 95.89% | |
revenue per share | 3.90 - | |||||
roe | 0.30 - | 0.64 112.22% | -0.17 126.36% | -0.41 145.47% | -0.03 93.30% | |
roic | 0.69 - | 0.64 7.97% | -0.17 126.21% | -0.34 102.93% | 0.00 101.39% | |
sales general and administrative to revenue | 0.25 - | |||||
shareholders equity per share | -1.20 - | -2.03 68.36% | 47.66 2,452.05% | 6.79 85.75% | 7.33 7.96% | |
stock based compensation to revenue | 0.10 - | |||||
tangible asset value | -15.52M - | -41.49M 167.37% | 298.72M 819.98% | 212.55M 28.84% | 242.36M 14.02% | |
tangible book value per share | -1.20 - | -2.03 68.36% | 47.66 2,452.05% | 6.79 85.75% | 7.33 7.96% | |
working capital | 15.52M - | 36.59M 135.82% | 291.98M 697.98% | 187.90M 35.65% | 210.97M 12.28% |
All numbers in USD (except ratios and percentages)